Cancer screening aims to distinguish cancer
before symptoms appear. It involves blood tests, DNA tests, urine tests,
medical imaging tests and other tests. The benefits of screening in terms of
cancer inhibition, early detection and subsequent treatment must be considered
against any harms.
According to study, “Latin
America Cancer Screening Market (2018-2023)” the key companies
operating in the Latin America cancer screening market are Abbott diagnostics,
GE Healthcare, Roche Diagnostics, Becton, Dickinson and Company, Hologic Inc.,
Roche Molecular Inc., Celera Group, Auto Genomics Inc., ELI Tech Group, Quest
Inc., Applied Biosystems Inc., Trans Genomic Inc., BioRad Laboratores Inc., PerkinELmer Inc. The
key players are scheduling for investing the attractive amount of money for
advancing the technologies and increasing the awareness related to this while
the government of an economy is also taking initiative in this regards and
creating the profitable strategies & policies which further proved to be profited
for both the consumer and players.
Based on type of cancer, cancer screening
market is segmented into breast cancer, bowel cancer, cervical cancer, lung
cancer, prostate cancer, colorectal cancer, oral cancer, skin cancer,
pancreatic cancer and other cancers. Breast cancer involves clinical breast
examination, mammography, Magnetic resonance imaging (MRI), and breast
self-examination tests. Cervical cancer involves Pap test and Human
papillomavirus (HPV) testing. Lung cancer involves Low-dose helical or spiral
computed tomography (CT or CAT) scan. Prostate cancer involves
Prostate-specific antigen (PSA) test and Digital rectal examination (DRE).
Colorectal cancer involves fecal occult blood test (FOBT), stool DNA tests,
colonoscopy test, double contrast barium enema and sigmoidoscopy test.
Additionally, skin cancer involves dermoscopy, skin self-examination and
complete skin exam test. Based on product type, market is segmented into
reagents & kits, services, instruments and data management system. Based on
screening type, market is bifurcated into the market is segmented into
laboratory tests, imaging tests, biopsy tests, genetic tests and endoscopy
tests. Imaging test make pictures or images of areas inside the body while
genetic test looks for certain gene mutations or changes that are linked to
types of cancer. In addition, based on end-users, market is segmented into
independent physicians & clinics, hospitals and laboratories.
The cancer screening market is driven by rise
in prevalence of target disorders, followed by increase in aging population,
rise in support from government in the form of awareness campaigns &
performance-based reimbursements, increase in awareness among people, and
presence of favorable government initiatives for early disease diagnosis.
However, high screening test costs, imbalance in socio-economic & political
scenario and inadequate healthcare access in developing countries may impact
the market.
Based on geography, cancer screening market is
segmented into Colombia, Brazil, and the rest of Latin America. It is
anticipated that market will be reached at fast pace owing to rise in
technological advancements and increase in incidence of chronic diseases over
the forecast period. It is expected that the market will be reached at US $
30.06 billion, by 2023, at a CAGR of 7.19%. It is projected that the cancer
screening market of will increase across the Latin America region more
positively over the coming years.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249